Phase I/II Study of Temozolomide and Gleevec (Imatinib Mesylate, Formerly Known as STI571) in Advanced Melanoma
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the safety and efficacy of combination therapy with Gleevec and Temzolomide in patients with advanced melanoma.
Interim analysis after accrual of 17 patients
United States: Institutional Review Board
|Abramson Cancer Center at University of Pennsylvania||Philadelphia, Pennsylvania 19104|